Alterity Therapeutics
ATHE
13 hedge funds and large institutions have $643K invested in Alterity Therapeutics in 2022 Q1 according to their latest regulatory filings, with 3 funds opening new positions, 1 increasing their positions, 3 reducing their positions, and 1 closing their positions.
200% more first-time investments, than exits
New positions opened: 3 | Existing positions closed: 1
19% more capital invested
Capital invested by funds: $541K → $643K (+$102K)
18% more funds holding
Funds holding: 11 → 13 (+2)
0% more ownership
Funds ownership: 0% → 0% (+0%)
67% less repeat investments, than reductions
Existing positions increased: 1 | Existing positions reduced: 3
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
+$19.6K |
| 2 |
Morgan Stanley
New York
|
+$16.7K |
| 3 |
VF
Virtu Financial
New York
|
+$16.3K |
| 4 |
T
TCWP
Beachwood,
Ohio
|
+$6.44K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$24.7K |
| 2 |
TSS
Two Sigma Securities
New York
|
-$8.26K |
| 3 |
UBS Group
Zurich,
Switzerland
|
-$2.58K |
| 4 |
CA
CoreCap Advisors
Southfield,
Michigan
|
-$1K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
1
Morgan Stanley
New York
| $481K | +$16.7K | +2,010 | +4% |
|
2
Envestnet Asset Management
Chicago,
Illinois
| $67K | – | – | – |
|
|
3
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
| $26K | -$24.7K | -2,971 | -48% |
|
|
4
Citadel Advisors
Miami,
Florida
| $19K | +$19.6K | +2,358 | New |
|
|
VF
5
Virtu Financial
New York
| $16K | +$16.3K | +1,959 | New |
|
|
6
UBS Group
Zurich,
Switzerland
| $9K | -$2.58K | -311 | -23% |
|
7
Geode Capital Management
Boston,
Massachusetts
| $9K | – | – | – |
|
|
TSS
8
Two Sigma Securities
New York
| $8K | -$8.26K | -994 | -49% |
|
|
T
9
TCWP
Beachwood,
Ohio
| $6K | +$6.44K | +775 | New |
|
|
PCA
10
Providence Capital Advisors
Charlotte,
North Carolina
| $2K | – | – | – |
|
|
CA
11
CoreCap Advisors
Southfield,
Michigan
| – | -$1K | -22 | Closed |
|
ATHE Hedge Fund Activity: Q1 2022 in Review
13 of the 6,340 institutional investors tracked by Wall St. Rank reported a position in Alterity Therapeutics (ATHE) for Q1 2022, worth a combined $643K — up 19% from $541K a quarter earlier.
Buyers outnumbered sellers: 3 funds opened new ATHE positions and 1 closed out — a net gain of 2 holders — while 1 added to existing stakes and 3 trimmed.
The largest buyer was Citadel Advisors, opening a new position worth an estimated $19.6K. The largest seller was Susquehanna International Group, cutting an estimated $24.7K.
- 13 institutional investors held Alterity Therapeutics (ATHE) as of Q1 2022, up from 11 in Q4 2021.
- Funds reported $643K of Alterity Therapeutics stock for Q1 2022, up 19% quarter-over-quarter.
- 3 funds opened new Alterity Therapeutics positions in Q1 2022 and 1 closed out, a net change of +2 holders.
- The largest Alterity Therapeutics buyer in Q1 2022 was Citadel Advisors, an estimated $19.6K added.
- The largest Alterity Therapeutics seller in Q1 2022 was Susquehanna International Group, an estimated $24.7K sold.
Based on aggregated 13F filings for Q1 2022.